- Source type
- Government
- Access type
- Official
- Publisher
- Health Resources and Services Administration
- Date
- 2026-05-27
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
91
Government health research
- Publisher type
- Government research
- Bias profile
- Low
This source is strongest for safety and clinical outcomes and weaker for consumer context and regulatory status.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 66/100
- Context Source
- Clinical outcomes
- 90/100
- Primary Anchor
- Mechanism
- 90/100
- Primary Anchor
- Safety
- 92/100
- Primary Anchor
- Consumer context
- 88/100
- Strong Support
- Trial discovery
- 89/100
- Strong Support
Best used for
- Research synthesis
- Public-health context
- Safety resources
Weak for
- Primary endpoint extraction when a study is available
Used in Viral Vitalism
World-First HIV-to-HIV Lung Transplant Expanded Donor Access
Roles: Regulatory status
Related studies
No structured study record is currently attached to this source.
Related sources
Federal Register: Final revised HOPE Act safeguards and research criteria
Regulatory background for HOPE Act transplant safeguards.
- Trust score
- 91
- Publisher
- Federal Register
- Access
- Official
- Usage
- 1 connection
CMS: Medicare GLP-1 Bridge launch announcement
Primary CMS source for the temporary Medicare GLP-1 Bridge access program.
- Trust score
- 91
- Publisher
- Centers for Medicare & Medicaid Services
- Access
- Official
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
FDA: North American coral snake antivenin expiration-date extension
Primary FDA safety and availability source for coral snake antivenin Lot CL6814 extension.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
Medicare.gov: Weight-loss drugs and Medicare GLP-1 Bridge
Patient-facing eligibility and coverage boundary for the Medicare GLP-1 Bridge.
- Trust score
- 91
- Publisher
- Medicare.gov
- Access
- Official
- Usage
- 1 connection
Reuters: FDA approves Vertex gene therapy for children as young as two
Independent wire confirmation for the Casgevy pediatric age-expansion brief.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 1 connection